Beilstein Journal of Organic Chemistry p. 155 - 161 (2015)
Update date:2022-08-16
Topics:
Johannes, Manuel
Reindl, Maximilian
Gerlitzki, Bastian
Schmitt, Edgar
Hoffmann-R?der, Anja
The development of selective anticancer vaccines that provide enhanced protection against tumor recurrence and metastasis has been the subject of intense research in the scientific community. The tumor-associated glycoprotein MUC1 represents a well-established target for cancer immunotherapy and has been used for the construction of various synthetic vaccine candidates. However, many of these vaccine prototypes suffer from an inherent low immunogenicity and are susceptible to rapid in vivo degradation. To overcome these drawbacks, novel fluorinated MUC1 glycopeptide-BSA/TTox conjugate vaccines have been prepared. Immunization of mice with the 4'F-TF-MUC1-TTox conjugate resulted in strong immune responses overriding the natural tolerance against MUC1 and producing selective IgG antibodies that are cross-reactive with native MUC1 epitopes on MCF-7 human cancer cells.
View MoreShandong Xingshun New Material Co., Ltd.
website:http://www.sd-xingshun.com
Contact:+86-519-86461196/+86-519-86464994
Address:Middle of Luhua East Road, Dingtao District
Shandong Wanda Organosilicon New Material Co., Ltd
Contact:+86-21-54177116;54302881
Address:R1318 Greenland No. 3 Lane 58 Xinjian East Rd., Minhang
VanderArk International Limited
Contact:86-10-82437576
Address:Qing He
website:http://www.vanzpharm.com/en/index.html
Contact:86-27-84492310
Address:FANHU INDUSTRY PARK
Contact:86-516-66656369
Address:The west road of Huaihai, Xuzhou, China
Doi:10.1021/jo00341a018
(1982)Doi:10.1007/s10562-011-0731-y
(2012)Doi:10.1016/S0040-4039(01)92754-6
(1977)Doi:10.1021/ja00344a022
(1983)Doi:10.1002/jps.2600771014
(1988)Doi:10.1002/anie.201006870
(2011)